Showing results (201-210 of 313) with videos related to

Sort By:
Pageof 32
Cancer|December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic dataHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
British Journal of Haematology|February 13, 2003
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemiaWilliam G Wierda, Marcella M Johnson, Kim-Anh Do, et al.
Cancer|June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinosideGuillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controlsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 24, 2013
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemiaPaolo Strati, Naval Daver, Farhad Ravandi, et al.
Leukemia & Lymphoma|August 10, 2013
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experienceOhad Benjamini, Hagop Kantarjian, Mary Beth Rios, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 21, 2014
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemiaStefan Faderl, Kumudha Balakrishnan, Deborah A Thomas, et al.
Blood|February 1, 2003
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyJorge E Cortes, Moshe Talpaz, Francis Giles, et al.
Blood|July 5, 2011
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemiaXavier C Badoux, Michael J Keating, Sijin Wen, et al.
Blood|March 17, 2012
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemiaAlireza Eghtedar, Srdan Verstovsek, Zeev Estrov, et al.
Pageof 32